Abstract
Abuse of psychostimulants presents a significant health and social problem worldwide. Traditionally, the dopaminergic system has received much attention for its role in the development and manifestation of addictive behavior. The identification of the close interaction between the dopaminergic and glutamatergic pathway and by extension the nitric oxide (NO) signaling pathway (the nitrergic system) have provided a broader scope on the mechanisms underlying the development of addictive behavior following exposure to cocaine and methamphetamine. NO signaling is associated with the acquisition and maintenance of several behavioral phenotypes induced by cocaine and methamphetamine (METH), as well as in METH-induced dopaminergic depletion. Because it appears that NO signaling influences response to reward, memory formation, and free radical-induced neurotoxicity, pharmacotherapies targeting NO signaling pathway may prove beneficial in the treatment of psychostimulants abuse.
Keywords: Adolescence, adulthood, cocaine, conditioned place preference, dopamine, methamphetamine, neurotoxicity, nitric oxide (NO), psychostimulant, sensitization.
Current Pharmaceutical Design
Title:Nitric Oxide (NO) Signaling as a Potential Therapeutic Modality Against Psychostimulants
Volume: 19 Issue: 40
Author(s): Shervin Liddie, Mara A. Balda and Yossef Itzhak
Affiliation:
Keywords: Adolescence, adulthood, cocaine, conditioned place preference, dopamine, methamphetamine, neurotoxicity, nitric oxide (NO), psychostimulant, sensitization.
Abstract: Abuse of psychostimulants presents a significant health and social problem worldwide. Traditionally, the dopaminergic system has received much attention for its role in the development and manifestation of addictive behavior. The identification of the close interaction between the dopaminergic and glutamatergic pathway and by extension the nitric oxide (NO) signaling pathway (the nitrergic system) have provided a broader scope on the mechanisms underlying the development of addictive behavior following exposure to cocaine and methamphetamine. NO signaling is associated with the acquisition and maintenance of several behavioral phenotypes induced by cocaine and methamphetamine (METH), as well as in METH-induced dopaminergic depletion. Because it appears that NO signaling influences response to reward, memory formation, and free radical-induced neurotoxicity, pharmacotherapies targeting NO signaling pathway may prove beneficial in the treatment of psychostimulants abuse.
Export Options
About this article
Cite this article as:
Liddie Shervin, Balda A. Mara and Itzhak Yossef, Nitric Oxide (NO) Signaling as a Potential Therapeutic Modality Against Psychostimulants, Current Pharmaceutical Design 2013; 19 (40) . https://dx.doi.org/10.2174/138161281940131209144527
DOI https://dx.doi.org/10.2174/138161281940131209144527 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acute Tonsillitis
Infectious Disorders - Drug Targets Comprehensive Comparison of Trace Metal Concentrations in Cancerous and Non-Cancerous Human Tissues
Current Medicinal Chemistry Re and Tc Complexes with Pyrazolyl-Containing Chelators: from Coordination Chemistry to Target-Specific Delivery of Radioactivity
Current Radiopharmaceuticals Multiple Non-Equivalent Interfaces Mediate Direct Activation of GABAA Receptors by Propofol
Current Neuropharmacology Nutrition and Immunity: Laboratory and Clinical Aspects
Current Pharmaceutical Design Targeting Conserved Pathways: Mitochondrial Dysfunction and Beyond
Current Neurovascular Research Recent Advancements in Anti-Migraine Drug Research: Focus on Attempts to Decrease Neuronal Hyperexcitability
Recent Patents on CNS Drug Discovery (Discontinued) Medical Treatment of Critical Limb Ischemia: Current State and Future Directions
Current Vascular Pharmacology Carbonic Anhydrase Inhibitors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents How do Glial Cells Contribute to Motor Control?
Current Pharmaceutical Design Interferon Therapy for Malignant Solid Tumors
Current Drug Therapy GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future
Current Pharmaceutical Design Comparable Neuroprotective Effects of Pergolide and Pramipexole on Ferrous Sulfate-Induced Dopaminergic Cell Death in Cell Culture
CNS & Neurological Disorders - Drug Targets What About Drug Checking? Systematic Review and Netnographic Analysis of Social Media
Current Neuropharmacology Cannabinoids and Neuroprotection in Motor-Related Disorders
CNS & Neurological Disorders - Drug Targets Machine Learning-based Virtual Screening and Its Applications to Alzheimer’s Drug Discovery: A Review
Current Pharmaceutical Design Effect of Synthetic Cannabinoid HU210 on Memory Deficits and Neuropathology in Alzheimers Disease Mouse Model
Current Alzheimer Research Meningococcal Disease and Future Drug Targets
CNS & Neurological Disorders - Drug Targets Hydroxyproline: A Potential Biochemical Marker and Its Role in the Pathogenesis of Different Diseases
Current Protein & Peptide Science Aldehyde Oxidase Activity and Inhibition in Hepatocytes and Cytosolic Fraction from Mouse, Rat,Monkey and Human
Drug Metabolism Letters